Shares of Corvus Pharmaceuticals Inc. (CRVS) have gained 100% over the past four months as the clinical-stage biopharmaceutical company anticipates a data release later this month.
The company's lead drug candidate is Soquelitinib (formerly known as CPI-818), an oral small molecule drug designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com